Last month, Nektar Therapeutics presented results for its experimental eczema treatment. The eczema treatment Nektar ...
The Atopic Dermatitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key ...
Pfizer delivered strong 2Q25 results with double-digit revenue growth and margin expansion. Click here to read why PFE stock ...
Zoryve cream gains FDA approval for treating mild to moderate atopic dermatitis in young children, offering a safe, ...
This approval follows the recent FDA approval of ruxolitinib cream 1.5% (Opzelura), a topical JAK inhibitor, as a treatment ...
True or False: Early data from a randomized trial showed that acetaminophen (Tylenol) led to a greater risk of eczema in ...
Investing.com -- Arcutis Biotherapeutics Inc (NASDAQ:ARQT) stock gained 1.5% in Monday’s premarket trading after the U.S. Food and Drug Administration approved its ZORYVE cream for treating mild to ...
In a challenge brought by competitor Sanofi, BBB National Programs’ National Advertising Division found certain Galderma ...
AbCellera Biologics eyes long-term growth with a new facility, clinical trial progress, and a pivot to proprietary drug ...
ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well ...
InvestorsHub on MSN
Arcutis Biotherapeutics Shares Rise After FDA Approves Eczema Cream for Young Children
Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) shares gained 1.5% in premarket trading Monday after the U.S. Food and Drug ...
The pharmaceutical giant has granted the president’s long-standing demands. Other drug companies could be next.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback